CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
IFN-alpha with retinoic aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001509
NCT00001509Phase 2Completed

A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor

National Cancer Institute (NCI)·interventional·Posted Dec 10, 2002·Updated Mar 4, 2008

In Brief

A Phase 2 clinical trial evaluating IFN-alpha with retinoic acid for Nephroblastoma and Neuroblastoma. Completed, across 1 site.

Detailed Summary

A body of preclinical data has provided a strong rationale for evaluating the combination of IFN-alpha with retinoic acid. The two drugs have different mechanisms of action and, when used in combination, show enhanced activity in both adult and pediatric tumor cell lines. The combination of the antiproliferative and differentiation inducing effect of retinoids together with the antiproliferative, immunostimulatory and differentiation-potentiating effects of IFN-alpha warrant clinical investigation of this combination for the treatment of refractory pediatric malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 10, 2002
Enrollment StartJul 1, 1996
Study CompletionMay 1, 2000
TodayJul 2, 2026
Posted 23.6 years ago

Interventions

IFN-alpha with retinoic aciddrug